http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2689278-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 2015-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b08aa509dadaeeda921685eec676df7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cf6e62b628c997f56f2d5baa0989014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc629b2287551ad28f725117cfce7ec3 |
| publicationDate | 2018-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2689278-T3 |
| titleOfInvention | Compounds of 2- (aryl or heteroaryl) phenyl (aza) benzofuran for the treatment of hepatitis C |
| abstract | A compound of Formula I, including the pharmaceutically acceptable salts thereof: ** Formula ** wherein m is 0 or 1; X is N or C-R10; R1 is methyl; R2 is Ar1; Ar1 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl, and is substituted with 0-3 substituents selected from the group of cyano, halo, alkyl, cycloalkyl, haloalkyl, OH, OR101, haloalkoxy, NH2, NR102R103, COOR101, CONR102R103 , S (O) 2R101, S (O) 2NR102R103 and NR101CONR102R103; R101 is hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; R102, R103 are each independently hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; or R102 and R103 can form a ring by joining two atoms, one of each of R102 and R103; R3 is hydrogen, halo or alkyl; R4, R5, R6, R7, R8 are each independently selected from the group of hydrogen, halo, alkyl, cycloalkyl, haloalkyl, halocycloalkyl, hydroxyalkyl, hydroxycycloalkyl, alkoxyalkyl, alkoxycycloalkyl, alkoxy, hydroxyalkyloxy, alkoxyalkyloxy, COOR20, R202) (R203); R201 is hydrogen, alkyl or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy and haloalkoxy; R202, R203 are each independently selected from the group of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkyl, alkynyl, cyclic ether, cyclic amine, lactams, bridged bicyclic alkyl, bicyclic alkyl, fused bicyclic ether, ether bridged bicyclic, spirobicyclic ether, fused bicyclic amine, bridged bicyclic amine and spirobicyclic amine, with 0-3 substituents selected from the group of halo, OH, OR104, NH2, NR105R106, COOR104, CONR105R106, S (O) 2R104, S (O) 2NR105R106, NR104CONR105R106, OR104CONR105R106, C (> = NR107) NR105R106, NR108C (> = NR107) NR105R106, haloalkoxy, Ar2, O-Ar2 and NR105-Ar2; or R202 and R203 can form a ring by joining two atoms, one of each of R202 and R203; R202 and R203 can also form bicyclic or tricyclic rings by joining multiple atoms of each of R202 and R203; R104 is hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; R105, R106 are each independently hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; or R105 and R106 can form a ring by joining two atoms, one of each of R105 and R106; R107, R108 are each independently hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; or R107 and R108 can form a ring by joining two atoms, one of each of R107 and R108; Ar2 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl and is substituted with 0-3 substituents selected from the group of cyano, halo, alkyl, cycloalkyl, haloalkyl, OH, OR204, haloalkoxy, NH2, NR205R206, COOR204, CONR205R206, S (O) 2R204, S (O) 2NR205R206 and NR204CONR205R206; R204 is hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; R205, R206 are each independently hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; or R205 and R206 can form a ring by joining two atoms, one of each of R205 and R206; R9 is selected from the group of hydrogen, halo, alkyl, haloalkyl, cycloalkyl, alkoxy, Ar3 and NR301R302; R301 is selected from the group of hydrogen, alkyl, cycloalkyl, (cycloalkyl) alkyl, benzyl, alkylcarbonyl, haloalkyl carbonyl, phenylcarbonyl, (alkoxyphenyl) carbonyl, alkylsulfonyl, phenylsulfonyl, (alkoxyphenyl) sulfonyl and (haloalkoxyphenyl) sulfonyl; R302 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl; or R301 and R302 taken together with the nitrogen to which they are attached are oxazolidinonyl or dioxothiazinyl; Ar3 is phenyl, 5-membered heteroaryl or 6-membered heteroaryl and is substituted with 0-3 substituents selected from the group of cyano, halo, alkyl, cycloalkyl, haloalkyl, OH, OR303, haloalkoxy, NH2, NR304R305, COOR303, CONR304R305, S (O) 2R303, S (O) 2NR304R305 and NR303CONR304R305; R303 is hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; R304, R305 are each independently hydrogen, alkyl, or cycloalkyl with 0-3 substituents selected from halo, hydroxyl, alkoxy, and haloalkoxy; or R304 and R305 can form a ring by joining two atoms, one of each of R304 and R305; R10 is hydrogen, alkyl, halo, N (R401) (R402) or alkylsulfonyl; R401 and R402 are each independently selected from the group of hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl or alkylsulfonylalkyl; or N (R401) (R402) taken together is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl and is substituted with 0-2 substituents selected from alkyl, hydroxyalkyl, and hydroxy, where "hydrogen" or "H" refers to hydrogen, including its isotopes, such as deuterium; "halo" means fluorine, chlorine, bromine, or iodine; "alkyl" means a linear or branched alkyl group consisting of 1 to 6 carbons; "alkenyl" means a linear or branched alkyl group consisting of 2 to 6 carbons with at least one double bond; "cycloalkyl" means a monocyclic ring system composed of 3 to 7 carbons; "hydroxyalkyl," "alkoxy" and other terms with a substituted alkyl moiety include linear and branched isomers composed of 1 to 6 carbon atoms for the alkyl moiety; "aryl" means a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 12 carbon atoms, or a fused bicyclic ring system in which one or both of the rings is a phenyl group; wherein fused bicyclic ring systems consist of a phenyl group fused to a four to six membered aromatic or non-aromatic carbocyclic ring; and "heteroaryl" means a 5- to 7-membered monocyclic aromatic ring system or an 8 to 11-membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. |
| priorityDate | 2014-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.